AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year - July 20, 2026

AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year Two milestones just turned AI drug discovery from promise into a real world test. Isomorphic Labs, the Google DeepMind spinoff built on the AlphaFold lineage, is moving its first AI designed molecules into human oncology trials, while Insilico Medicine has pushed rentosertib, an AI discovered treatment for the lung disease idiopathic pulmonary fibrosis, into a pivotal Phase 3 study. With roughly 60 billion dollars invested since 2019, around 200 AI originated programs in human trials, and still zero FDA approvals, Chris and Laura dig into why 2026 is the year AI designed medicines finally have to prove they actually work. Hosted by Chris and Laura. The DX Today Podcast brings you daily deep dives into the most consequential stories in the AI ecosystem. #AI #DrugDiscovery #AlphaFold #Biotech #ClinicalTrials